4
NEWS
Disadvantages need
addressing
H pylori
eradication
in T2D
A 14-day treatment regimen with
vonoprazan plus amoxicillin has
been found to be effective and
safe for eradicating Helicobacter
pylor (H pylori) infections in
patients with Type 2 diabetes
(T2D), with superior eradication
rates achieved in those
avoiding smoking and achieving
glycaemic control.
A common cause of
stomach ulcers (peptic ulcers),
Helicobacter pylori (see link
below) infection occurs when
Helicobacter pylori (H. pylori)
bacteria infect your stomach,
usually during childhood.
Developing a safe and effective
H pylori eradication regimen
for patients with diabetes is
essential because they are more
susceptible to such infections
and have a greater risk for
treatment failure than individuals
without T2D.
Researchers conducted a trial
in a hospital in China between
April and December 2023 to
study the safety and effectiveness
of vonoprazan-amoxicillin
dual therapy in patients with
T2D diagnosed with H pylori
infection. Along with standard
medications to manage T2D, the
patients received vonoprazan
and amoxicillin dual therapy for
14 days.
Among the 75 patients
enrolled, the eradication rate of
H pylori was found to be 84%.
Adverse events occurred in 13.3%
of patients, with no reports of
any severe adverse events; almost
all patients (93.3%) showed good
compliance with the dual therapy.
For more on H. pylori
click HERE.
Following the recent United
Through Diabetes educational event,
the DWRF is sharing a series of
interviews from the day with leading
healthcare professionals and people
working in diabetes.
This includes a round-table
interview of people from diverse
communities following the panel
session 'Tackling Diabetes Inequity in
Black Populations - Lived Experience
Perspectives'. The panel included:
• Dr Bernadette Adeyileka-Tracz
- Executive Director of Diabetes
Africa
• Barbara Hudson - The Queen
Elizabeth Hospital Birmingham,
Clinical Nurse Specialist in Diabetes
• Amelia Glasgow - Living with type 1
diabetes
• Daniel Newman - Award-winning
diabetes advocate. Host of The
Talking Type 1 Podcast.
• Tilieka Hendricks - Diabetes
Africa, living with diabetes for four
years, without confirmed diagnosis
When asked why was the diverse
communities session so important,
Barbara Hudson commented:
"Working in diabetes we are finding
that there as a disparity with the
uptake in insulin pump therapy,
continuous glucose monitoring. We
know that these new technologies
can improve outcomes and quality
of life in all groups with diabetes.
But it appears that there has been a
disadvantage within black and ethnic
populations, and this is something
that we need to be tackling."
Bernadette Adeyileka-Tracz
added: "It is important because there
is a lack of awareness that black
populations in the UK actually have
inequity of outcomes and access.
The primary objective for me was
to highlight some examples of that.
We gave some examples in diabetes
technology, being well prepared
for pregnancy and also in renal
replacement therapy, like people
with chronic kidney disease who
are living with diabetes. In each of
those examples, we showed that
black populations in the UK were
worse off."
To find out more, CLICK HERE.